Given our observation that TGF-β is required for anti-tumor immune responses, along with other data showing that TGF-β-blockade can enhance carcinogenesis through tumor cell-intrinsic mechanisms[48-50], the use of TGF-β inhibitors in a chemopreventive mode should be undertaken with caution. Here, TGFB1 is linked to neoplasm.